Six Gilead Sciences Trials Halted Following Deaths Involving Idelalisib (Zydelig) Drug
Gilead Sciences has immediately halted the continuation of six clinical trials. The US Food and Drug Administration (FDA) says that the use of Idelaslisib (Zydelig) has led to serious adverse events and several deaths in clinical trial participants. Idelaslisib is used, in combination with other medications, to treat relapsed chronic lymphocytic leukemia (CLL). It is… Continue reading